Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Marine Drugs
|
October 21, 2009
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium
Herlinde Dumez, Enrique Gallardo, Stephane Culine, et al.
Investigational New Drugs
|
July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
Ramón Salazar, Ruth Plummer, Ana Oaknin, et al.
Marine Drugs
|
July 13, 2011
Plitidepsin has a safe cardiac profile: a comprehensive analysis
Arturo Soto-Matos, Sergio Szyldergemajn, Sonia Extremera, et al.
Investigational New Drugs
|
November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors
Luis Paz-Ares, Martin Forster, Valentina Boni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2014
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors
María Elena Elez, Josep Tabernero, David Geary, et al.
Investigational New Drugs
|
January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule
Antonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
Haematologica
|
October 16, 2012
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Vincent Ribrag, Dolores Caballero, Christophe Fermé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
María Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
The Lancet. Oncology
|
August 8, 2020
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Marine Drugs
|
October 21, 2009
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium
Herlinde Dumez, Enrique Gallardo, Stephane Culine, et al.
Investigational New Drugs
|
July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
Ramón Salazar, Ruth Plummer, Ana Oaknin, et al.
Marine Drugs
|
July 13, 2011
Plitidepsin has a safe cardiac profile: a comprehensive analysis
Arturo Soto-Matos, Sergio Szyldergemajn, Sonia Extremera, et al.
Investigational New Drugs
|
November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors
Luis Paz-Ares, Martin Forster, Valentina Boni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2014
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors
María Elena Elez, Josep Tabernero, David Geary, et al.
Investigational New Drugs
|
January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule
Antonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
Haematologica
|
October 16, 2012
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Vincent Ribrag, Dolores Caballero, Christophe Fermé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
María Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
The Lancet. Oncology
|
August 8, 2020
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau, et al.
Page
of 1